Cargando…

Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence

Targeting peroxisome proliferator-activated receptors (PPARs) has received increasing interest as a potential strategy to treat substance use disorders due to the localization of PPARs in addiction-related brain regions and the ability of PPAR ligands to modulate dopamine neurotransmission. Robust e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matheson, Justin, Le Foll, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291117/ https://www.ncbi.nlm.nih.gov/pubmed/32408505 http://dx.doi.org/10.3390/cells9051196

Ejemplares similares

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders
por: Cho, Min-Chul, et al.
Publicado: (2008)

Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder
por: Barone, Rita, et al.
Publicado: (2019)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo
por: Du, Lingyao, et al.
Publicado: (2017)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis
por: Lima, Emerson de Andrade, et al.
Publicado: (2013)

Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARα agonist) in smokers
por: Gendy, Marie N. S., et al.
Publicado: (2018)

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
por: Stunes, Astrid K, et al.
Publicado: (2011)

Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic Disorders
por: Ren, Ping, et al.
Publicado: (2015)

Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures
por: Oyama, Takuji, et al.
Publicado: (2009)

Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress
por: Sekulic-Jablanovic, Marijana, et al.
Publicado: (2017)

Astaxanthin as a Peroxisome Proliferator-Activated Receptor (PPAR) Modulator: Its Therapeutic Implications
por: Choi, Chang-Ik
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor (PPAR) γ and PPARα Agonists Modulate Mitochondrial Fusion-Fission Dynamics: Relevance to Reactive Oxygen Species (ROS)-Related Neurodegenerative Disorders?
por: Zolezzi, Juan M., et al.
Publicado: (2013)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
por: Sagheddu, Claudia, et al.
Publicado: (2021)

Benzoxazinones as Human Peroxisome Proliferator Activated Receptor Gamma (PPARγ) Agonists: A Docking Study Using Glide
por: Das, N., et al.
Publicado: (2011)

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
por: Araki, Masaya, et al.
Publicado: (2018)

Downregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposis
por: Cardell, Lars-Olaf, et al.
Publicado: (2005)

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer
por: Huang, Runzhi, et al.
Publicado: (2020)

Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Trophoblast Functions
por: Peng, Lin, et al.
Publicado: (2021)

PPAR-Alpha Agonists as Novel Antiepileptic Drugs: Preclinical Findings
por: Puligheddu, Monica, et al.
Publicado: (2013)

Fishing for Targets of Alien Metabolites: A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Agonist from a Marine Pest
por: Vitale, Rosa Maria, et al.
Publicado: (2018)

Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs
por: Murphy, Thomas, et al.
Publicado: (2020)

Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health
por: Matheson, Justin, et al.
Publicado: (2020)

Impacts of recreational cannabis legalization on use and harms: A narrative review of sex/gender differences
por: Matheson, Justin, et al.
Publicado: (2023)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?
por: Green, David E., et al.
Publicado: (2011)

Expression of the Peroxisome Proliferator-Activated Receptors (PPARs) in the Hepatic Stellate Cells
por: Sato, Takeya, et al.
Publicado: (2004)

Peroxisome Proliferator-Activated Receptor (PPAR): Balance for Survival in Parasitic Infections
por: Chan, Marion M., et al.
Publicado: (2010)

Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2018)

Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review
por: Butler, Kevin, et al.
Publicado: (2019)

Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists
por: El-Zahabi, Mohamed Ayman, et al.
Publicado: (2022)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

The isolation, Characterization and Preclinical Studies of Metal Complex of Thespesia populnea for the Potential Peroxisome Proliferator-activated Receptors-γ Agonist Activity
por: Phanse, Mohini Ashok, et al.
Publicado: (2015)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours
por: Marques, A R, et al.
Publicado: (2004)

Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice
por: Michalik, Liliane, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_e9bp0mub8htbj64pp54bs9m6tr